Phaseline

Companies › Prothya Biosolutions

Prothya Biosolutions: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Hematology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Human apotransferrin
Transferrin replacement protein
TFPhase 2Congenital AtransferrinemiaJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01797055Human apotransferrinPhase 2Congenital AtransferrinemiaHematologyJan 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

TF (1)

Companies with the same targets

–

Companies built like this

S-INFINITY Pharmaceuticals Imara Shanghai RAAS Blood Products Pharmanutra Vega Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.